

External Quality Assessment Scheme

Hepatitis A, antibodies Round 1, 2023

Specimens

Please find enclosed 3 human plasma or serum samples S001, S002 and S003, each 0.6 mL.

Caution

Quality control specimens derived from human blood must be handled with the same care as patient samples, i.e. as potential transmitters of serious diseases. The specimens may contain infectious viruses. The specimens have not been inactivated.

Examinations

HAVAb
HAVAbG
HAVAbM
Clinical interpretation

Storage and use

After arrival, the samples should be stored at +2...8 °C, and used as soon as possible, preferably within a week. The samples are ready for use. Analyse as patient samples.

Result reporting

Please enter the results and methods via LabScala (www.labscala.com). If you cannot find your instrument or reagent from the registry, please contact the EQA Coordinator. Report only the results of examinations that are in use in your laboratory. All reported examinations will be scored.

S001



S002



S003



2023-02-07

INSTRUCTIONS

Product no. 5092
LQ773223011-013/FI
UN3373

Subcontracting: Sample preparation, sample pretesting

If the kit is incomplete or contains damaged specimens, please report immediately to info@labquality.fi.

The results should be reported no later than **March 1, 2023.**

The expected results of the round are published in LabScala in the View Reports section by March 6, 2023.

Inquiries

EQA Coordinator
Marsa Järvenpää
marsa.jarvenpaa@labquality.fi

Labquality Oy

Kumpulantie 15
FI-00520 HELSINKI
Finland

Tel. + 358 9 8566 8200
Fax + 358 9 8566 8280

info@labquality.fi
www.labquality.com




Client report

	No of participants	No of responded participants	Response percentage
Hepatitis A, antibodies, February, 1-2023	89	87	97.8 %

Summary

Overall success rate by samples




Summary	Own score	Max score	Own success rate	Difference	AVR success rate
Sample S001	8	8	100 %	1.3 %	98.7 %
Sample S002	4	4	100 %	1 %	99 %
Sample S003	8	8	100 %	1.7 %	98.3 %
Average:			100 %	1.4 %	98.6 %

History	Test nr.	Own success rate	Difference	AVR success rate
History not found				


Sample S001

Sample S001 success rate




Sample S001 results	Responded	Own score	Max score	Own success rate	Difference	AVR success rate	Count
	Clinical interpretation	4	4	100 %	1.6 %	98.4 %	93
	HAVAb	-	-	-	-	94.9 %	39
	HAVAbG	2	2	100 %	0 %	100 %	39
	HAVAbM	2	2	100 %	0 %	100 %	91
	Total:	8	8	100 %	1.3 %	98.7 %	262

Sample S001 Clinical interpretation




Clinical interpretation	Interpretation	Further action	Interpretation count	Further action count	Own score	Max score	Own success rate	Difference	AVR success rate
	<input checked="" type="radio"/> Old immunity/vaccinated		52		4	4	100 %	0 %	100 %
		Would be referred to another laboratory for further examination		1	-	-			
		New sample requested		2	-	-			
	No indication of acute/recent infection		11		-				100 %
		New sample requested		1	-	-			
	No indication of past infection/immunity		1		-				0 %
	Laboratory does not give clinical interpretation		29		-				-
		Would be referred to another laboratory for further examination		2	-	-			
	Total:		93		4	4	100 %	1.6 %	98.4 %

Sample S001 HAVAb




■ Negative ■ Positive

Sample S001 HAVAbG



■ Positive

Sample S001 HAVAbM



■ Negative

HAVAb	Interpretation	Methodics	Interpretation count	Methodics count	Own score	Max score	Own success rate	Difference	AVR success rate
	Negative		2		-				0 %
		Abbott Architect HAVAb total		1					
		Roche cobas/Modular/Elecsys anti-HAV		1					
	Positive		37		-				100 %
		Abbott Architect HAVAb total		1					
		Bayer Advia Centaur HAV Total		7					
		bioMérieux Vidas anti-HAV Total		4					
		Diasorin Liaison anti-HAV		3					
		Ortho Vitros anti-HAV Total		1					
		Roche cobas/Modular/Elecsys anti-HAV		14					
		Siemens Atellica HAV Total		7					
	Total:		39		-	-	-	-	94.9 %

OWN DEVICE: ARCHITECT


HAVAbG	Interpretation	Methodics	Interpretation count	Methodics count	Own score	Max score	Own success rate	Difference	AVR success rate
	<input checked="" type="radio"/> Positive		39		2	2	100 %	0 %	100 %
		Abbott Alinity i HAVAb-IgG		20					
		<input checked="" type="radio"/> Abbott Architect HAVAb-IgG		18					
		Nal von minden NADAL HAV IgG		1					
	Total:		39		2	2	100 %	0 %	100 %

OWN DEVICE: ARCHITECT

HAVAbM	Interpretation	Methodics	Interpretation count	Methodics count	Own score	Max score	Own success rate	Difference	AVR success rate
	<input checked="" type="radio"/> Negative		91		2	2	100 %	0 %	100 %
		Abbott Alinity i HAVAb-IgM		22					
		<input checked="" type="radio"/> Abbott Architect HAVAb-IgM		20					
		Bayer Advia Centaur HAV IgM		6					
		bioMérieux Vidas HAV IgM		6					
		Diasorin Liaison HAV IgM		4					
		Intermedical HAV IgM		1					
		Nal von Minden NADAL HAV IgM		1					
		Ortho Vitros HAV IgM		3					
		Roche cobas/Modular/Elecsys anti-HAV IgM		20					
		Siemens Atellica HAV IgM		8					
	Total:		91		2	2	100 %	0 %	100 %


Sample S002

Sample S002 success rate




Sample S002 results	Responded	Own score	Max score	Own success rate	Difference	AVR success rate	Count
	Clinical interpretation	-	-	-	-	98.4 %	93
	HAVAb	-	-	-	-	97.4 %	39
	HAVAbG	2	2	100 %	0 %	100 %	39
	HAVAbM	2	2	100 %	0 %	100 %	89
	Total:	4	4	100 %	1 %	99 %	260

Sample S002 Clinical interpretation




Clinical interpretation	Interpretation	Further action	Interpretation count	Further action count	Own score	Max score	Own success rate	Difference	AVR success rate
	No indication of acute/recent infection		33		-				100 %
		New sample requested		5	-	-			
		Would be referred to another laboratory for further examination		1	-	-			
	No indication of past infection/immunity		28		-				100 %
		New sample requested		3	-	-			
		Would be referred to another laboratory for further examination		1	-	-			
	Old immunity/vaccinated		1		-				0 %
	<input checked="" type="radio"/> Laboratory does not give clinical interpretation		31		-				-
		New sample requested		1	-	-			
		Would be referred to another laboratory for further examination		1	-	-			
	Total:		93		-	-	-	-	98.4 %

Sample S002 HAVAb




■ Negative ■ Positive

Sample S002 HAVAbG



■ Negative

Sample S002 HAVAbM



■ Negative

HAVAb	Interpretation	Methodics	Interpretation count	Methodics count	Own score	Max score	Own success rate	Difference	AVR success rate
	Negative		38		-				100 %
		Abbott Architect HAVAb total		2					
		Bayer Advia Centaur HAV Total		7					
		bioMérieux Vidas anti-HAV Total		4					
		Diasorin Liaison anti-HAV		3					
		Ortho Vitros anti-HAV Total		1					
		Roche cobas/Modular/Elecsys anti-HAV		14					
		Siemens Atellica HAV Total		7					
	Positive		1		-				0 %
		Roche cobas/Modular/Elecsys anti-HAV		1					
	Total:		39		-	-	-	-	97.4 %

OWN DEVICE: ARCHITECT


HAVAbG	Interpretation	Methodics	Interpretation count	Methodics count	Own score	Max score	Own success rate	Difference	AVR success rate
	<input checked="" type="radio"/> Negative		39		2	2	100 %	0 %	100 %
		Abbott Alinity i HAVAb-IgG		20					
		<input checked="" type="radio"/> Abbott Architect HAVAb-IgG		18					
		Nal von minden NADAL HAV IgG		1					
	Total:		39		2	2	100 %	0 %	100 %

OWN DEVICE: ARCHITECT

HAVAbM	Interpretation	Methodics	Interpretation count	Methodics count	Own score	Max score	Own success rate	Difference	AVR success rate
	<input checked="" type="radio"/> Negative		89		2	2	100 %	0 %	100 %
		Abbott Alinity i HAVAb-IgM		22					
		<input checked="" type="radio"/> Abbott Architect HAVAb-IgM		20					
		Bayer Advia Centaur HAV IgM		6					
		bioMérieux Vidas HAV IgM		6					
		Diasorin Liaison HAV IgM		3					
		Intermedical HAV IgM		1					
		Nal von Minden NADAL HAV IgM		1					
		Ortho Vitros HAV IgM		3					
		Roche cobas/Modular/Elecsys anti-HAV IgM		19					
		Siemens Atellica HAV IgM		8					
	Total:		89		2	2	100 %	0 %	100 %


Sample S003

Sample S003 success rate



Sample S003 results	Responded	Own score	Max score	Own success rate	Difference	AVR success rate	Count
	Clinical interpretation	4	4	100 %	1.6 %	98.4 %	93
	HAVAb	-	-	-	-	97.4 %	39
	HAVAbG	2	2	100 %	0 %	100 %	39
	HAVAbM	2	2	100 %	2.2 %	97.8 %	91
	Total:	8	8	100 %	1.7 %	98.3 %	262


Sample S003 Clinical interpretation



■ Acute/recent infection
■ Old immunity/vaccinated
■ Laboratory does not give clinical interpretation

Clinical interpretation	Interpretation	Further action	Interpretation count	Further action count	Own score	Max score	Own success rate	Difference	AVR success rate
	<input checked="" type="radio"/> Acute/recent infection		63		4	4	100 %	0 %	100 %
		Would be referred to another laboratory for further examination		15	-	-			
		New sample requested		10	-	-			
	Old immunity/vaccinated		1		-	-			0 %
	Laboratory does not give clinical interpretation		29		-	-			-
		Would be referred to another laboratory for further examination		6	-	-			
		New sample requested		1	-	-			
	Total:		93		4	4	100 %	1.6 %	98.4 %

Sample S003 HAVAb




■ Negative ■ Positive

Sample S003 HAVAbG



■ Positive

Sample S003 HAVAbM



■ Negative ■ Positive

HAVAb	Interpretation	Methodics	Interpretation count	Methodics count	Own score	Max score	Own success rate	Difference	AVR success rate
	Negative		1		-				0 %
		Roche cobas/Modular/Elecsys anti-HAV		1					
	Positive		38		-				100 %
		Abbott Architect HAVAb total		2					
		Bayer Advia Centaur HAV Total		7					
		bioMérieux Vidas anti-HAV Total		4					
		Diasorin Liaison anti-HAV		3					
		Ortho Vitros anti-HAV Total		1					
		Roche cobas/Modular/Elecsys anti-HAV		14					
		Siemens Atellica HAV Total		7					
	Total:		39		-	-	-	-	97.4 %

OWN DEVICE: ARCHITECT

HAVAbG	Interpretation	Methodics	Interpretation count	Methodics count	Own score	Max score	Own success rate	Difference	AVR success rate
	<input checked="" type="radio"/> Positive		39		2	2	100 %	0 %	100 %
		Abbott Alinity i HAVAb-IgG		20					
		<input checked="" type="radio"/> Abbott Architect HAVAb-IgG		18					
		Nal von minden NADAL HAV IgG		1					
	Total:		39		2	2	100 %	0 %	100 %

OWN DEVICE: ARCHITECT

HAVAbM	Interpretation	Methodics	Interpretation count	Methodics count	Own score	Max score	Own success rate	Difference	AVR success rate
	Negative		2		-				0 %
		Abbott Alinity i HAVAb-IgM		1					
		Nal von Minden NADAL HAV IgM		1					
	<input checked="" type="radio"/> Positive		89		2	2	100 %	0 %	100 %
		Abbott Alinity i HAVAb-IgM		21					
		<input checked="" type="radio"/> Abbott Architect HAVAb-IgM		20					
		Bayer Advia Centaur HAV IgM		6					
		bioMérieux Vidas HAV IgM		6					
		Diasorin Liaison HAV IgM		4					
		Intermedical HAV IgM		1					
		Ortho Vitros HAV IgM		3					
		Roche cobas/Modular/Elecsys anti-HAV IgM		20					
		Siemens Atellica HAV IgM		8					
	Total:		91		2	2	100 %	2.2 %	97.8 %

Report Info**PARTICIPANTS**

Altogether 89 laboratories from 21 countries participated in this EQA round.

REPORT INFO

The results are divided into groups according to the method stated by the laboratory and presented in laboratory-specific tables. Accepted results are marked with green color and laboratory's own result with a black radio button . In the scoring report you will find summaries of overall success rate and sample specific success rates (%). Sample specific interpretations are shown in pie diagrams as percentages and the total interpretation and methodic counts in the tables. If you have not reported any results you will get a note: "You have not responded in time, only global report is available."

For information on report interpretation and performance evaluation, please see the "EQAS Interpretation guidelines" in LabScala User instructions. In case you have any questions regarding the reports, please contact the EQA Coordinator.

SCORING

The round is scored based on test results and clinical interpretations when 60% or more of the participants report the expected result and when at least three results are reported.

The following general rules are applied:

Correct/expected test result 2/2 points
False/deviating test result 0/2 points
Correct/expected clinical interpretation 4/4 points
False/deviating clinical interpretation 0/4 points


The performance of the laboratory is assessed by the Own success rate (%). The target is 100%. The examination-specific scores obtained by the laboratory in the round are converted to Own success rate per sample (scores/maximum scores*100). The Laboratory's Own success rate is the average of the sample success rates.

The success rate for the entire round (AVR success rate) is calculated from the total number of scores given to the results per sample (all scores/maximum scores*100). The AVG success rate of the entire round is the average of the sample success rates. The difference in the Laboratory's Own success rate (%) to the corresponding numbers for the entire round is shown in the table.

GLOBAL REPORT

	No of participants	No of responded participants	Response percentage
Hepatitis A, antibodies, February, 1-2023	89	87	97.8 %


Summary



Summary	AVR success rate
Sample S001	98.7 %
Sample S002	99 %
Sample S003	98.3 %
Average:	98.6 %


Sample S001

Sample S001 success rate



Sample S001 results	Responded	AVR success rate	Count
	Clinical interpretation	98.4 %	93
	HAVAb	94.9 %	39
	HAVAbG	100 %	39
	HAVAbM	100 %	91
	Total:	98.7 %	262

Sample S001 Clinical interpretation



Clinical interpretation	Interpretation	Further action	Interpretation count	Further action count	AVR success rate	Interpretation Score	Further action Score
	Old immunity/vaccinated		52		100 %	4	
		Would be referred to another laboratory for further examination		1	-		-
		New sample requested		2	-		-
	No indication of acute/recent infection		11		100 %	4	
		New sample requested		1	-		-
	No indication of past infection/immunity		1		0 %	0	
	Laboratory does not give clinical interpretation		29		-	-	
		Would be referred to another laboratory for further examination		2	-		-
	Total:		93		98.4 %		

Sample S001 HAVAb




■ Negative ■ Positive

Sample S001 HAVAbG



■ Positive

Sample S001 HAVAbM



■ Negative


HAVAb	Interpretation	Methodics	Interpretation count	Methodics count	AVR success rate	Interpretation Score
	Negative		2		0 %	0
		Abbott Architect HAVAb total		1		
		Roche cobas/Modular/Elecsys anti-HAV		1		
	Positive		37		100 %	2
		Abbott Architect HAVAb total		1		
		Bayer Advia Centaur HAV Total		7		
		bioMérieux Vidas anti-HAV Total		4		
		Diasorin Liaison anti-HAV		3		
		Ortho Vitros anti-HAV Total		1		
		Roche cobas/Modular/Elecsys anti-HAV		14		
		Siemens Atellica HAV Total		7		
	Total:		39		94.9 %	

HAVAbG	Interpretation	Methodics	Interpretation count	Methodics count	AVR success rate	Interpretation Score
	Positive		39		100 %	2
		Abbott Alinity i HAVAb-IgG		20		
		Abbott Architect HAVAb-IgG		18		
		Nal von minden NADAL HAV IgG		1		
	Total:		39		100 %	

HAVAbM	Interpretation	Methodics	Interpretation count	Methodics count	AVR success rate	Interpretation Score
	Negative		91		100 %	2
		Abbott Alinity i HAVAb-IgM		22		
		Abbott Architect HAVAb-IgM		20		
		Bayer Advia Centaur HAV IgM		6		
		bioMérieux Vidas HAV IgM		6		
		Diasorin Liaison HAV IgM		4		
		Intermedical HAV IgM		1		
		Nal von Minden NADAL HAV IgM		1		
		Ortho Vitros HAV IgM		3		
		Roche cobas/Modular/Elecsys anti-HAV IgM		20		
		Siemens Atellica HAV IgM		8		
	Total:		91		100 %	


Sample S002

Sample S002 success rate




Sample S002 results	Responded	AVR success rate	Count
	Clinical interpretation	98.4 %	93
	HAVAb	97.4 %	39
	HAVAbG	100 %	39
	HAVAbM	100 %	89
	Total:	99 %	260

Sample S002 Clinical interpretation




Clinical interpretation	Interpretation	Further action	Interpretation count	Further action count	AVR success rate	Interpretation Score	Further action Score
	No indication of acute/recent infection		33		100 %	4	
		New sample requested		5	-		-
		Would be referred to another laboratory for further examination		1	-		-
	No indication of past infection/immunity		28		100 %	4	
		New sample requested		3	-		-
		Would be referred to another laboratory for further examination		1	-		-
	Old immunity/vaccinated		1		0 %	0	
	Laboratory does not give clinical interpretation		31		-	-	
		New sample requested		1	-		-
		Would be referred to another laboratory for further examination		1	-		-
	Total:		93		98.4 %		

Sample S002 HAVAb



■ Negative ■ Positive

Sample S002 HAVAbG



■ Negative

Sample S002 HAVAbM



■ Negative


HAVAb	Interpretation	Methodics	Interpretation count	Methodics count	AVR success rate	Interpretation Score
	Negative		38		100 %	2
		Abbott Architect HAVAb total		2		
		Bayer Advia Centaur HAV Total		7		
		bioMérieux Vidas anti-HAV Total		4		
		Diasorin Liaison anti-HAV		3		
		Ortho Vitros anti-HAV Total		1		
		Roche cobas/Modular/Elecsys anti-HAV		14		
		Siemens Atellica HAV Total		7		
	Positive		1		0 %	0
		Roche cobas/Modular/Elecsys anti-HAV		1		
	Total:		39		97.4 %	

HAVAbG	Interpretation	Methodics	Interpretation count	Methodics count	AVR success rate	Interpretation Score
	Negative		39		100 %	2
		Abbott Alinity i HAVAb-IgG		20		
		Abbott Architect HAVAb-IgG		18		
		Nal von minden NADAL HAV IgG		1		
	Total:		39		100 %	

HAVAbM	Interpretation	Methodics	Interpretation count	Methodics count	AVR success rate	Interpretation Score
	Negative		89		100 %	2
		Abbott Alinity i HAVAb-IgM		22		
		Abbott Architect HAVAb-IgM		20		
		Bayer Advia Centaur HAV IgM		6		
		bioMérieux Vidas HAV IgM		6		
		Diasorin Liaison HAV IgM		3		
		Intermedical HAV IgM		1		
		Nal von Minden NADAL HAV IgM		1		
		Ortho Vitros HAV IgM		3		
		Roche cobas/Modular/Elecsys anti-HAV IgM		19		
		Siemens Atellica HAV IgM		8		
	Total:		89		100 %	

Sample S003

Sample S003 success rate



Sample S003 results	Responded	AVR success rate	Count
	Clinical interpretation	98.4 %	93
	HAVAb	97.4 %	39
	HAVAbG	100 %	39
	HAVAbM	97.8 %	91
	Total:	98.3 %	262


Sample S003 Clinical interpretation



■ Acute/recent infection
■ Old immunity/vaccinated
■ Laboratory does not give clinical interpretation

Clinical interpretation	Interpretation	Further action	Interpretation count	Further action count	AVR success rate	Interpretation Score	Further action Score
	Acute/recent infection		63		100 %	4	
		Would be referred to another laboratory for further examination		15	-		-
		New sample requested		10	-		-
	Old immunity/vaccinated		1		0 %	0	
	Laboratory does not give clinical interpretation		29		-	-	
		Would be referred to another laboratory for further examination		6	-		-
		New sample requested		1	-		-
	Total:		93		98.4 %		

Sample S003 HAVAb




■ Negative ■ Positive

Sample S003 HAVAbG



■ Positive

Sample S003 HAVAbM



■ Negative ■ Positive

HAVAb	Interpretation	Methodics	Interpretation count	Methodics count	AVR success rate	Interpretation Score
	Negative		1		0 %	0
		Roche cobas/Modular/Elecsys anti-HAV		1		
	Positive		38		100 %	2
		Abbott Architect HAVAb total		2		
		Bayer Advia Centaur HAV Total		7		
		bioMérieux Vidas anti-HAV Total		4		
		Diasorin Liaison anti-HAV		3		
		Ortho Vitros anti-HAV Total		1		
		Roche cobas/Modular/Elecsys anti-HAV		14		
		Siemens Atellica HAV Total		7		
	Total:		39		97.4 %	

HAVAbG	Interpretation	Methodics	Interpretation count	Methodics count	AVR success rate	Interpretation Score
	Positive		39		100 %	2
		Abbott Alinity i HAVAb-IgG		20		
		Abbott Architect HAVAb-IgG		18		
		Nal von minden NADAL HAV IgG		1		
	Total:		39		100 %	

HAVAbM	Interpretation	Methodics	Interpretation count	Methodics count	AVR success rate	Interpretation Score
	Negative		2		0 %	0
		Abbott Alinity i HAVAb-IgM		1		
		Nal von Minden NADAL HAV IgM		1		
	Positive		89		100 %	2
		Abbott Alinity i HAVAb-IgM		21		
		Abbott Architect HAVAb-IgM		20		
		Bayer Advia Centaur HAV IgM		6		
		bioMérieux Vidas HAV IgM		6		
		Diasorin Liaison HAV IgM		4		
		Intermedical HAV IgM		1		
		Ortho Vitros HAV IgM		3		
		Roche cobas/Modular/Elecsys anti-HAV IgM		20		
		Siemens Atellica HAV IgM		8		
	Total:		91		97.8 %	

Report Info**PARTICIPANTS**

Altogether 89 laboratories from 21 countries participated in this EQA round.

REPORT INFO

The results are divided into groups according to the method stated by the laboratory and presented in laboratory-specific tables. Accepted results are marked with green color and laboratory's own result with a black radio button . In the scoring report you will find summaries of overall success rate and sample specific success rates (%). Sample specific interpretations are shown in pie diagrams as percentages and the total interpretation and methodic counts in the tables. If you have not reported any results you will get a note: "You have not responded in time, only global report is available."

For information on report interpretation and performance evaluation, please see the "EQAS Interpretation guidelines" in LabScala User instructions. In case you have any questions regarding the reports, please contact the EQA Coordinator.

SCORING

The round is scored based on test results and clinical interpretations when 60% or more of the participants report the expected result and when at least three results are reported.

The following general rules are applied:

Correct/expected test result 2/2 points
False/deviating test result 0/2 points
Correct/expected clinical interpretation 4/4 points
False/deviating clinical interpretation 0/4 points

The performance of the laboratory is assessed by the Own success rate (%). The target is 100%. The examination-specific scores obtained by the laboratory in the round are converted to Own success rate per sample (scores/maximum scores*100). The Laboratory's Own success rate is the average of the sample success rates.

The success rate for the entire round (AVR success rate) is calculated from the total number of scores given to the results per sample (all scores/maximum scores*100). The AVG success rate of the entire round is the average of the sample success rates. The difference in the Laboratory's Own success rate (%) to the corresponding numbers for the entire round is shown in the table.

External Quality Assessment Scheme

Hepatitis A, antibodies Round 1, 2023

Specimens

Samples of this EQA round were human plasma or serum, each of which originated from a single donor. Based on the pre-testing and the results obtained in the round, the samples were homogeneous, stable and suitable for the external quality assessment scheme. The materials were sent without temperature control packaging.

The expected results were as follows:

Sample S001 (LQ773223011)

HAVAb	Positive
HAVAbG	Positive
HAVAbM	Negative
Clinical interpretation	No indication of acute/recent infection or Old immunity/vaccinated

Sample S002 (LQ773223012)

HAVAb	Negative
HAVAbG	Negative
HAVAbM	Negative
Clinical interpretation	No indication of acute/recent infection or No indication of past infection/immunity

Sample S003 (LQ773223013)

HAVAb	Positive
HAVAbG	Positive
HAVAbM	Positive
Clinical interpretation	Acute/recent infection

Pre-test methods: Abbott Alinity i HAVAb-IgG/IgM, bioMérieux VIDAS anti-HAV Total and VIDAS HAV IgM

Report info

Please see the description of the data analysis on the last page of the laboratory-specific reports and global reports. It is important to read the Final report first, because it contains important information of the samples and results in each round.

Comments – EQA Coordinator

The EQA round went well for the participants. Only a few deviating results were reported, of which the incorrect results reported by one participant appeared to be due to sample mix-up.

Exceptions in scoring

No exceptions.

End of report

2023-03-06

FINAL REPORT

Product no. 5092

Subcontracting: Sample preparation, sample pretesting

Samples sent	2023-02-07
Round closed	2023-03-01
Expected results	2023-03-02
Final report	2023-03-06

Request for correction

Typing errors in laboratory's result forms are on laboratory's responsibility. Labquality accepts responsibility only for result processing. Requests must be notified by writing within three weeks from the date of this letter.

Authorized by

EQA Coordinator
Marsa Järvenpää
marsa.jarvenpaa@labquality.fi

Expert

MD, PhD, Adjunct professor,
Specialist in Clinical Microbiology,
Maija Lappalainen,
HUSLAB, Helsinki, Finland.

Labquality Oy

Kumpulantie 15
FI-00520 HELSINKI
Finland

Tel. + 358 9 8566 8200

Fax + 358 9 8566 8280

info@labquality.fi
www.labquality.com



Copyright © Labquality Oy

Labquality does not permit any reproduction for commercial purposes of any portion of the material subject to this copyright. Labquality prohibits any use of its name, or reference to Labquality EQA program, or material in this report in any advertising, brochures or other commercial publications. Labquality EQA data do not necessarily indicate the superiority of instruments, reagents, testing equipments or materials used by participating laboratories. Use of Labquality EQA data to suggest superiority or inferiority of equipments or materials may be deceptive and misleading. Proficiency test results are handled confidentially. Labquality will not issue any statements to third parties of the performance of laboratories in external quality assessment schemes unless otherwise agreed.